2023
Immuno-chemotherapy as single treatment modality for larynx preservation (ICoLP): Co-primary endpoints and safety results.
Ferrarotto R, Johnson F, Hutcheson K, Sui D, Johnson J, Ebersole B, Mott F, Lewis C, Bonini F, Hoff C, Mitani Y, Cortez M, Bell D, El-Naggar A, Gunn G, Fuller C, Myers J, Lee J, Rosenthal D, Diaz E. Immuno-chemotherapy as single treatment modality for larynx preservation (ICoLP): Co-primary endpoints and safety results. Journal Of Clinical Oncology 2023, 41: 6008-6008. DOI: 10.1200/jco.2023.41.16_suppl.6008.Peer-Reviewed Original ResearchTreatment-related adverse eventsPathologic complete responseLarynx squamous cell carcinomaCo-primary endpointsEarly recurrenceCommon treatment-related adverse eventsStage IIDisease control rateLaryngeal preservation rateSolitary lung metastasisRelapse-free survivalSquamous cell carcinomaLoss of insuranceSingle treatment modalityAUC 6Eligible ptsEvaluable patientsImmuno-chemotherapyLarynx biopsiesDefinitive radiotherapyEfficacy endpointPrimary endpointRECIST 1.1Secondary endpointsAdverse events
2022
Long-term outcomes of a phase II trial of neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN).
Gross N, Ferrarotto R, Amit M, Nagarajan P, Yuan Y, Bell D, Johnson J, Morrison W, Rosenthal D, Glisson B, Johnson F, Mott F, Esmaeli B, Diaz E, Gidley P, Goepfert R, Lewis C, Wargo J, Weber R, Myers J. Long-term outcomes of a phase II trial of neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN). Journal Of Clinical Oncology 2022, 40: 9519-9519. DOI: 10.1200/jco.2022.40.16_suppl.9519.Peer-Reviewed Original ResearchPathologic complete responseOverall response rateCutaneous squamous cell carcinomaPhase II trialPathologic responseLong-term outcomesNeoadjuvant immunotherapySquamous cell carcinomaAdverse eventsCSCC-HNII trialCell carcinomaGrade 2 adverse eventsPilot phase II trialGrade 3 diarrheaMajor pathologic responsePathologic partial responseAdjuvant radiation therapyWarrants further investigationMedian followRECIST v1.1Adjuvant radiationPrimary endpointRecurrent diseaseSecondary endpoints